Anticancer efficacy of ibrutinib-loaded plga nanoparticles against breast cancer mcf-7 cell lines

Ibrutinib (IBR) is reported as a poorly water-soluble drug due to which its dissolution rate and oral bioavailability are very poor. In this study, IBR loaded poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles (NPs) were prepared by nano-precipitation method using stabilizer (Pluronic acid 127). The prepared NPs were evaluated for particle size, PDI, DSC, FT-IR, SEM, drug entrapment efficiency (EE%), in vitro drug release and cell line anticancer study. The mean particle size, PDI, %EE of optimized IBR loaded PLGA-NPs (F2) were found 445.8 ± 5.53 nm, 0.603, and 97.37%, respectively. In vitro release followed zero order kinetics and a Fickian transport mechanism; the optimized NPs (F2) approximately released 89% of the drug over 24 h. SEM images and surface morphology confirmed that nanoparticles were spherical and had smooth surfaces. An MTT assay was conducted in the breast cell lines (MCF-7) to evaluate anti-cancerous activity of IBR. IBR loaded PLGA-NPs (F2) showed a high potential against breast cancer cells.